FDFabio Didonè

Fabio Didonè

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabio Didonè has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toronto Staging Guidelines for Wilms Tumour: The Meeting Point Between Clinicians and Epidemiologists—Results of the BENCHISTA-ITA Project

    by Laura Botta, Fabio Didonè, Riccardo Capocaccia, Massimo Conte, Marcella Sessa, Fabio Savoia, Andrea Di Cataldo, Marta Arrabito, Milena Maria Maule, Gemma Gatta, et al.

    Background/Objectives: Despite overall excellent outcomes for Wilms tumour, regional variations in stage at diagnosis and care pathways remain a concern across Europe. We evaluated stage distribution, three-year survival, and treatment patterns in Italy, considering hospital care as a proxy for healthcare capacity and migration. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 148 patients (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the Italian population. Stage was classified according to the Toronto guidelines. Information on treatment and diagnosed/treating hospitals was collected. Stage at diagnosis was further refined using probabilistic linkage with the clinical registry 1.01 Model. Overall survival, defined as all-cause mortality, was estimated using the Kaplan–Meier method. Results: Most patients presented with localized disease (77%), 32% Stage I, while 19% were Stage IV. Three-year survival analysis showed significant differences between stages, ranging from 98% in patients with Stage I to 78% in the ones with Stage IV. No significant disparity across the Italian regions was observed in stage distribution or survival. Diagnoses and treatments were mostly (>90%) centralized in the same region for patients residing in the Centre or North of Italy. However, the cross-regional health migration from the South was of about 30% for diagnosis and larger for treatments. Conclusions: This study shows that standardized staging improves data comparability and highlights challenges in managing metastatic cases and regional care pathways. The results support the use of clinical and PBCR information to interpret survival patterns and guide improvements in paediatric oncology care.

  • Open Access

    Neuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project—A Population-Based Study

    by Gemma Gatta, Riccardo Capocaccia, Massimo Conte, Marcella Sessa, Fabio Savoia, Carlotta Sacerdote, Walter Mazzucco, Rosalia Ragusa, Fabio Didonè, Laura Botta, et al.

    Background: Neuroblastoma is the most common embryonal cancer. Since several population-based studies in Europe have revealed differences in 5-year survival across countries and regions. Objectives: We principally investigated the impact of stage at diagnosis on survival in Italy. Methods: Data were obtained from 26 population-based cancer registries (PBCRs), covering 319 cases (ages 0–14) diagnosed between 2013 and 2017, representing about 80% of the national population. Stage was classified according to the Toronto guidelines. Information on treatment and treating hospitals was also collected. Stage at diagnosis was further refined using probabilistic linkage with the Italian Neuroblastoma Registry (RINB). Results: Overall survival (OS), defined as all-cause mortality, was estimated using the Kaplan–Meier method. Most patients presented with stage M disease (37%), while a small proportion remained unclassified (2%). Three-year survival analysis showed significant differences between stages, ranging from >95% in localised (stage I) and MS stages to 78% in stage M (stage IV). No significant disparity across the Italian regions was observed in stage distribution or survival. Surgery and radiotherapy treatments of neuroblastoma were mostly centralized in the Centre and North of Italy. However, the cross-regional health migration from the South was limited to, and interpreted as appropriate for, high-volume centres. Conclusions: This population-based study highlights the high quality of care provided to children with neuroblastoma by an effective national clinical network. Compared with previous studies, we observed very limited variation across regions. A national childhood cancer registry remains essential to obtain a comprehensive picture of the country.

  • Open Access

    Improving the Connection Between Population-Based and National Clinical Pediatric Cancer Registries—A Pilot Study on Neuroblastoma: The Italian BENCHISTA-Ita Project

    by Fabio Didonè, Andrea Tittarelli, Claudio Tresoldi, Paolo Contiero, Riccardo Capocaccia, Riccardo Haupt, Martina Fragola, Marcella Sessa, Fabio Savoia, Carlotta Sacerdote, et al.

    Background: Childhood cancers (CC) are rare and treatable; however, survival rates vary across Europe, with poorer outcomes in Eastern countries. Stage at diagnosis is one of the major prognostic factors. The BENCHISTA-Ita project aims to promote the use of the Toronto Guidelines by population-based cancer registries (PBCR) to standardize stage at diagnosis data collection. In Italy, regional cancer registries ensure data quality, while national clinical registries centralize pediatric cancer data. The aim of the study is to promote the linkage between PBCRs and national clinical registries to enhance data completeness. This study presents the results of linking BENCHISTA-Ita neuroblastoma cases with the Italian Neuroblastoma Registry (RINB) as a pilot study. Methods: The linkage process involved probabilistic matching using R software, considering variables such as sex, year of birth, and residence at diagnosis. The study included 294 neuroblastoma cases from BENCHISTA-Ita and 578 from RINB, diagnosed between 2013 and 2017. Results: Results showed that 272 of 294 BENCHISTA-Ita cases matched with RINB cases, improving the completeness of clinical variables such as stage at diagnosis, N-Myc amplification, and relapse/progression. The linkage increased the completeness of clinical variables in PBCR, such as stage at diagnosis from 81% to 99%, N-Myc from 47% to 86%, and relapse/progression from 68% to 98%. Additionally, the linkage improved RINB’s follow-up completeness from 59% to 97% and added new cases in both PBCR and RINB. Conclusions: This linkage demonstrates the potential to enrich both databases, improving data quality and harmonization of cancer indicators. The study highlights the importance of collaboration between PBCRs and clinical registries to ensure comprehensive data collection and enhance more informative population-based studies. Future efforts will focus on expanding the linkage to other national clinical registries.


  • Open Access

    Comparative analysis of 5-year relative survival in adolescents and young adults with cancer relative to both children and adults in Europe (EUROCARE-6): Results from a population-based study

    by Annalisa Trama, Silvia Rossi, Damien Bennet, Charles Stiller, Keiu Paapsi, Xavier Troussard, Fabiola Giudici, Henrike E. Karim-Kos, Francesco Cerza, Jan Trallero, et al.


  • Open Access

    Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe

    by Laura Botta, Riccardo Capocaccia, Claudia Vener, Alice Bernasconi, Annalisa Trama, Fabio Didoné, Elena Demuru, Roberta De Angelis, Silvia Rossi, S. Mohsen Mousavi, et al.


  • Open Access

    Corrigendum to “Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results” [Eur J Cancer 213 (2024):115079]

    by Alice Indini, Fabio Didoné, Daniela Massi, Susana Puig, Jordi Rubio Casadevall, Damien Bennett, Alexander Katalinic, Arantza Sanvisens, Andrea Ferrari, Paolo Lasalvia, et al.

  • Open Access

    Incidence and prognosis of cutaneous melanoma in European adolescents and young adults (AYAs): EUROCARE-6 retrospective cohort results

    by Alice Indini, Fabio Didoné, Daniela Massi, Susana Puig, Jordi Rubio Casadevall, Damien Bennett, Alexander Katalinic, Arantza Sanvisens, Andrea Ferrari, Paolo Lasalvia, et al.


  • Open Access

    International benchmarking of childhood cancer survival by stage at diagnosis: The BENCHISTA project protocol

    by Laura Botta, Gemma Gatta, Fabio Didonè, Angela Lopez Cortes, Kathy Pritchard-Jones, the BENCHISTA Project Working Group

    Background: Several studies have shown significant variation in overall survival rates from childhood cancer between countries, using population-based cancer registry (PBCR) data for all cancers combined and for many individual tumour types among children. Without accurate and comparable data on Tumour stage at diagnosis, it is difficult to define the reasons for these survival differences. This is because measurement systems designed for adult cancers do not apply to children’s cancers and cancer registries often hold limited information on paediatric tumour stage and the data sources used to define it.Aims: The BENCHISTA project aims to test the application of the international consensus “Toronto Staging Guidelines” (TG) for paediatric tumours by European and non-European PBCRs for six common paediatric solid tumours so that reliable comparisons of stage at diagnosis and survival rates by stage can be made to understand any differences. A secondary aim is to test the data availability and completeness of collection of several ‘Toronto’ consensus non-stage prognostic factors, treatment types given, occurrence of relapse/progression and cause of death as a descriptive feasibility study.Methods: PBCRs will use their permitted data access channels to apply the Toronto staging guidelines to all incident cases of six solid childhood cancers (medulloblastoma, osteosarcoma, Ewings sarcoma, rhabdomyosarcoma, neuroblastoma and Wilms tumour) diagnosed in a consecutive three-year period within 2014–2017 in their population. Each registry will provide a de-identified patient-level dataset including tumour stage at diagnosis, with only the contributing registry holding the information that would be needed to re-identify the patients. Where available to the registry, patient-level data on ‘Toronto’ non-stage prognostic factors, treatments given and clinical outcomes (relapse/progression/cause of death) will be included. More than 60 PBCRs have been involved in defining the patient-level dataset items and intend to participate by contributing their population-level data. Tumour-specific on-line training workshops with clinical experts are available to cancer registry staff to assist them in applying the Toronto staging guidelines in a consistent manner. There is also a project-specific help desk for discussion of difficult cases and promotion of the CanStaging online tools, developed through the International Association of Cancer Registries, to further ensure standardisation of data collection. Country-specific stage distribution and observed survival by stage at diagnosis will be calculated for each tumour type to compare survival between countries or large geographical regions.Discussion: This study will be promote and enhance the collection of standardized staging data for childhood cancer by European and non-European population-based cancer registries. Therefore, this project can be seen as a feasibility project of widespread use of Toronto Staging at a population-level by cancer registries, specifying the data sources used and testing how well standardized the processes can be. Variation in tumour stage distribution could be due to real differences, to different diagnostic practices between countries and/or to variability in how cancer registries assign Toronto stage. This work also aims to strengthen working relationships between cancer registries, clinical services and cancer-specific clinical study groups, which is important for improving patient outcomes and stimulating research.